The Ties

December 9, 2014

(Genome Web) – About a third of members of the US Food and Drug Administration panels that evaluated devices for use in cardiology, orthopedics, and gynecology between 2012 and 2014 had received compensation from medical device companies, according to the Wall Street Journal. Overall, about 10 percent of advisors had received something of value from a company whose product they were evaluating, and, the Journal‘s Joseph Walker notes, FDA disclosed just 1 percent of these conflicts.